Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) have been assigned an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $40.20.

ZLAB has been the topic of several research reports. Weiss Ratings upgraded Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 29th. Wall Street Zen cut shares of Zai Lab from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Zacks Research upgraded shares of Zai Lab from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Finally, Citigroup increased their target price on shares of Zai Lab from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Friday.

Insiders Place Their Bets

In other news, Director William Lis sold 7,040 shares of the stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $18.09, for a total transaction of $127,353.60. Following the completion of the transaction, the director directly owned 50,437 shares in the company, valued at $912,405.33. This represents a 12.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Yajing Chen sold 2,264 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $17.46, for a total value of $39,529.44. Following the completion of the transaction, the chief financial officer owned 35,691 shares of the company’s stock, valued at $623,164.86. The trade was a 5.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 90,873 shares of company stock valued at $1,730,096 in the last three months. 4.88% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Zai Lab stock. SG Americas Securities LLC increased its stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,396 shares of the company’s stock after buying an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Zai Lab Price Performance

ZLAB opened at $23.32 on Tuesday. The company has a market capitalization of $2.65 billion, a price-to-earnings ratio of -13.64 and a beta of 0.78. The business’s 50-day moving average price is $18.75 and its two-hundred day moving average price is $19.25. Zai Lab has a 1 year low of $15.96 and a 1 year high of $36.77.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings data on Tuesday, June 30th. The company reported ($0.50) earnings per share for the quarter. The firm had revenue of $106.31 million for the quarter. Zai Lab had a negative return on equity of 26.42% and a negative net margin of 41.86%. Sell-side analysts anticipate that Zai Lab will post -2.23 earnings per share for the current fiscal year.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.